WO2020089637A1 - Formulation aérosolisable - Google Patents
Formulation aérosolisable Download PDFInfo
- Publication number
- WO2020089637A1 WO2020089637A1 PCT/GB2019/053092 GB2019053092W WO2020089637A1 WO 2020089637 A1 WO2020089637 A1 WO 2020089637A1 GB 2019053092 W GB2019053092 W GB 2019053092W WO 2020089637 A1 WO2020089637 A1 WO 2020089637A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aerosolisable formulation
- acid
- amount
- nicotine
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
- A24B15/241—Extraction of specific substances
- A24B15/243—Nicotine
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/32—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by acyclic compounds
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/05—Devices without heating means
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/10—Devices using liquid inhalable precursors
Definitions
- the present disclosure relates to an aerosolisable formulation, a method of forming the same, a container containing the same, a device containing the same and processes and uses of the same.
- Electronic aerosol provision systems such as e-cigarettes generally contain a reservoir of liquid which is to be vaporised, typically containing nicotine.
- a heater is activated to vaporise a small amount of liquid, which is therefore inhaled by the user.
- Aerosols from e-cigarettes and smoke from tobacco products such as cigarettes provides to the user a complex chain of flavour in the mouth, nicotine absorption in the mouth and throat, followed by nicotine absorption in the lungs.
- Nicotine contributes to a number of these factors, and is strongly associated with factors such as impact, irritation and smoothness; these are readily perceived by consumers, and e-cigarettes may offer too much or too little of these parameters for consumers, depending upon individual preferences. Nicotine reward is particularly complex as it results from both the amount of and speed with which nicotine is absorbed from the lining of the mouth, this is typically nicotine in the vapour phase, and from the amount and speed nicotine that is absorbed from the lungs, this is typically nicotine in the particulate phase of the aerosol which is inhaled. Each of these factors, and their balance, can strongly contribute to consumer acceptability of an e- cigarette. Providing means to optimise the overall vaping experience is therefore desirable to e-cigarette manufacturers. A further challenge facing such systems is the continued demand for harm reduction. Harm from cigarette and e-cigarette devices primarily comes from toxicants. Therefore, there is a desire to reduce or remove the components which may form toxicants.
- an aerosolisable formulation comprising
- the aerosolisable formulation may contain no flavours that can be encapsulated by the one or more cyclodextrins.
- an aerosolisable formulation comprising
- a process for forming an aerosol comprising aerosolising an aerosolisable formulation comprising
- the aerosolisable formulation may contain no flavours that can be encapsulated by the one or more cyclodextrins.
- a process for forming an aerosol comprising aerosolising an aerosolisable formulation comprising
- a contained aerosolisable formulation comprising (a) a container; and (b) an aerosolisable formulation , comprising (i) water in an amount of at least 85 wt.% based on the aerosolisable formulation; and (ii) nicotine.
- the aerosolisable formulation may contain no flavours that can be encapsulated by the one or more cyclodextrins.
- a contained aerosolisable formulation comprising
- an electronic aerosol provision system comprising:(a) an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system;(b) a power supply comprising a cell or battery for supplying power to the aerosoliser (c) an aerosolisable formulation , comprising (i) water in an amount of at least 85 wt.% based on the aerosolisable formulation; and(ii) nicotine or one or more flavours.
- the aerosolisable formulation may contain no flavours that can be encapsulated by the one or more cyclodextrins.
- an electronic aerosol provision system comprising:
- a power supply comprising a cell or battery for supplying power to the aerosoliser
- an aerosolisable formulation comprising (i) water in an amount of at least 85 wt.% based on the aerosolisable formulation; and (ii) nicotine.
- a process for forming an aerosol comprising aerosolising an aerosolisable formulation comprising
- an advantageous system may be provided in which an aerosolisable formulation contains a very high content of water and is used to deliver nicotine and/or flavour.
- the very high water content provides a sensory perception for the user which is desirably close to the nicotine‘hit’ and/or flavour release provided by tobacco based cigarettes.
- This desirable nicotine‘hit’ and/or flavour release is in contrast to ‘traditional’ e-liquids based on glycerol and propylene glycol which users sometimes do not use because of the perceived differences in respect of nicotine‘hit’ and/or flavour release provided by tobacco based cigarettes.
- water-based system may be provided in which aerosolised formulation is formed from an aerosolisable formulation at a low temperature. This is in contrast to‘traditional’ e-cigarettes which use a heater, typically applied to liquids based on glycerol and propylene glycol to form an aerosolised formulation.
- a heater typically applied to liquids based on glycerol and propylene glycol to form an aerosolised formulation.
- the provision of such a system and the avoidance of heating may address problems of the prior art relating to the formation of toxicants. More specifically, we have identified a water-based system which, by selection of a very high water content delivers desirable nicotine‘hit’ and/or flavour release but avoids the need to use the heaters associated with prior liquids based on glycerol and propylene glycol.
- the number of components present may be reduced leading to less chance of forming breakdown products/toxicants.
- the use of water allows for the replacement of some or all of the glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof typically used in e-cigarettes.
- the aerosolisable formulation comprises water in an amount of at least 85 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 87 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 89 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 91 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 93 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 95 wt.% based on the aerosolisable formulation.
- water is present in an amount of at least 97 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.1 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.2 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.3 wt.% based on the aerosolisable formulation.
- water is present in an amount of at least 99.4 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.5 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.6 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.7 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.8 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99.9 wt.% based on the aerosolisable formulation.
- water is present in an amount of from 85 to 99.9 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 90 to 99.9 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 92 to 99.9 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 94 to 99.9 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 95 to 99.9 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 96 to 99.9 wt.% based on the aerosolisable formulation.
- water is present in an amount of from 97 to 99.9 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 98 to 99.9 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 99 to 99.9 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof.
- the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 5 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol, propylene glycol, and mixtures thereof.
- the aerosolisable formulation contains glycerol in an amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 1 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains glycerol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol.
- the aerosolisable formulation contains propylene glycol in an amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 1 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.2 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no propylene glycol.
- the aerosolisable formulation further comprises an acid.
- the acid may be any suitable acid.
- the acid is an organic acid.
- the acid is a carboxylic acid.
- the acid is an organic carboxylic acid.
- the acid is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
- the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, lactic acid, sorbic acid, and mixtures thereof.
- the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, and mixtures thereof.
- the acid is at least citric acid.
- the acid consists of citric acid.
- the acid is selected from acids having a pka of from 2 to 5. In one aspect the acid is a weak acid. In one aspect the acid is a weak organic acid.
- the acid may be present in any suitable amount. In one aspect the acid is present in an amount of no greater than 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 6 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.02 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 5 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.08 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 4 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.02 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 3 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.05 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 2 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.08 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 1 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.1 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.6 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.1 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.5 wt% based on the aerosolisable formulation.
- the acid is present in an amount of no greater than 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.1 wt% based on the aerosolisable formulation.
- the acid is present in an amount of from 0.01 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.1 wt% based on the aerosolisable formulation.
- the acid has a solubility in water of at least 2g/L at 20 °C. In one aspect the acid has a solubility in water of at least 5g/L at 20 °C. In one aspect the acid has a solubility in water of at least 10g/L at 20 °C. In one aspect the acid has a solubility in water of at least 20g/L at 20 °C. In one aspect the acid has a solubility in water of at least 50g/L at 20 °C. In one aspect the acid has a solubility in water of at least 100g/L at 20 °C. In one aspect the acid has a solubility in water of at least 200g/L at 20 °C.
- the acid has a solubility in water of at least 300g/L at 20 °C. In one aspect the acid has a solubility in water of at least 400g/L at 20 °C. In one aspect the acid has a solubility in water of at least 500g/L at 20 °C. In one aspect the acid has a solubility in water of at least 600g/L at 20 °C. In one aspect the acid has a solubility in water of at least 700g/L at 20 °C. In one aspect the acid has a solubility in water of at least 800g/L at 20 °C. In one aspect the acid has a solubility in water of at least 900g/L at 20 °C. In one aspect the acid has a solubility in water of at least 1000g/L at 20 °C. In one aspect the acid has a solubility in water of at least 1100g/L at 20°C.
- the amount of acid and the solubility of the acid may be selected such that a given amount of the acid will dissolve in the water.
- the amount of acid and the solubility of the acid may be selected such that a given amount of the acid will dissolve in the water.
- at 20 °C at least 20% of the acid dissolves in the water.
- at 25 °C at least 20% of the acid dissolves in the water.
- at 30 °C at least 20% of the acid dissolves in the water.
- In one aspect at 20 °C at least 35% of the acid dissolves in the water.
- at 20 °C at least 40% of the acid dissolves in the water.
- In one aspect at 20 °C at least 45% of the acid dissolves in the water.
- at 20 °C at least 50% of the acid dissolves in the water.
- at 20 °C at least 55% of the acid dissolves in the water.
- the molar ratio of acid to nicotine may be selected as desired.
- the molar ratio of acid to nicotine is from 5:1 to 1 :5.
- the molar ratio of acid to nicotine is from 4:1 to 1 :4.
- the molar ratio of acid to nicotine is from 3:1 to 1 :3.
- the molar ratio of acid to nicotine is from 2:1 to 1 :2.
- the molar ratio of acid to nicotine is from 1.5:1 to 1 :1.5.
- the molar ratio of acid to nicotine is from 1.2:1 to 1 :1.2.
- the molar ratio of acid to nicotine is from 5:1 to 1 :1.
- the molar ratio of acid to nicotine is from 4:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 3:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 2:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 1.5:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 1.2:1 to 1 : 1. In one aspect the total content of acid present in the formulation is no greater than 5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 1 mole equivalents based on the nicotine.
- the total content of acid present in the formulation is no less than 0.01 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.05 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.1 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.7 mole equivalents based on the nicotine.
- Nicotine formulations may be provided having desirable properties of flavour, impact, irritation, smoothness and/or nicotine reward for the user.
- nicotine is present in an amount of no greater than 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 6 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.01 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 4 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.01 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 3 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.01 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 2 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.01 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 1 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.01 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 1 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of no greater than 0.6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.6 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.1 to 0.6 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.5 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.08 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.2 wt% based on the total weight of the aerosolisable formulation.
- nicotine is present in an amount of from 0.08 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.1 wt% based on the total weight of the aerosolisable formulation.
- nicotine may exist in unprotonated form, monoprotonated form or diprotonated form.
- the structures of each of these forms are given below.
- references in the specification to protonated form means both monoprotonated nicotine and diprotonated nicotine. Reference in the specification to amounts in the protonated form means the combined amount of monoprotonated nicotine and diprotonated nicotine. Furthermore, when reference is made to a fully protonated formulation it will be understood that at any one time there may be very minor amounts of unprotonated nicotine present, e.g. less than 1 % unprotonated.
- the formulation may comprise nicotine in protonated form. In one aspect the formulation may comprise nicotine in unprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in monoprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in diprotonated form. In one aspect the formulation comprises nicotine in unprotonated form, nicotine in monoprotonated form and nicotine in diprotonated form.
- n one aspect at least 5wt% of the nicotine present in the formulation is in protonated form n one aspect at least 10wt% of the nicotine present n the formulation is in protonated form n one aspect at least 15wt% of the nicotine present n the formulation is in protonated form n one aspect at least 20wt% of the nicotine present n the formulation is in protonated form n one aspect at least 25wt% of the nicotine present n the formulation is in protonated form n one aspect at least 30wt% of the nicotine present n the formulation is in protonated form n one aspect at least 35wt% of the nicotine present n the formulation is in protonated form n one aspect at least 40wt% of the nicotine present n the formulation is in protonated form n one aspect at least 45wt% of the nicotine present n the formulation is in protonated form n one aspect at least 50wt% of the nicotine present n the formulation is in protonated form n one aspect at least 55wt% of the nicotine present
- the nicotine present in the formulation is in protonated form. In one aspect from 55 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 60 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 65 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 70 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 75 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 80 to 95 wt% of the nicotine present in the formulation is in protonated form.
- Nicotine 3-(1-methylpyrrolidin-2-yl) pyridine
- Nicotine is a diprotic base with pKa of 3.12 for the pyridine ring and 8.02 for the pyrrolidine ring It can exist in pH-dependent protonated (mono- and di-) and non-protonated (free base) forms which have different bioavailability.
- the fraction of non-protonated nicotine will be predominant at high pH levels whilst a decrease in the pH will see an increase of the fraction of protonated nicotine (mono- or di- depending on the pH). If the relative fraction of protonated nicotine and the total amount of nicotine in the sample are known, the absolute amount of protonated nicotine can be calculated.
- the relative fraction of protonated nicotine in formulation can be calculated by using the Henderson-Hasselbalch equation, which describes the pH as a derivation of the acid dissociation constant equation, and it is extensively employed in chemical and biological systems.
- [B] is the amount of non-protonated nicotine (i.e. free base)
- [BH+] the amount of protonated nicotine (i.e. conjugate acid)
- the relative fraction of protonated nicotine can be derived from the alpha value of the non-protonated nicotine calculated from the Henderson-Hasselbalch equation as:
- the aerosolisable formulation may comprise one or more flavours or flavouring components.
- flavours or flavouring components include extracts (e.g.
- the one or more flavours may be selected from the group consisting of (4-(para-)methoxyphenyl)-2-butanone, vanillin, y- undecalactone, menthone, 5-propenyl guaethol, menthol, para-mentha-8-thiol-3-one and mixtures thereof.
- the flavour is at least menthol.
- the one or more flavours may be present in any suitable amount. In one aspect the one or more flavours are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation.
- the one or more flavours are present in a total amount of no greater than 3 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 1wt.% based on the aerosolisable formulation.
- the one or more flavours are present in a total amount of from 0.01 to 5wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 4wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 3wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 1wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 0.5wt.% based on the aerosolisable formulation.
- the aerosolisable formulation contains one or more cyclodextrins, then the aerosolisable formulation contains no flavours that can be encapsulated by the one or more cyclodextrins. In one aspect, if the aerosolisable formulation contains one or more cyclodextrins, then the aerosolisable formulation contains no flavours. As will be appreciated, one or more cyclodextrins may or may not be present in any suitable amount in the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 12 wt.% based on the aerosolisable formulation.
- the one or more cyclodextrins are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 9 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation.
- the one or more cyclodextrins are present in a total amount of no greater than 6 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 3 wt.% based on the aerosolisable formulation.
- the one or more cyclodextrins are present in a total amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 1 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.001 wt.% based on the aerosolisable formulation.
- the aerosolisable formulation of the present invention may comprise one or more cyclodextrins.
- the one or more cyclodextrins may be selected from the group consisting of unsubstituted cyclodextrins, substituted cyclodextrins and mixtures thereof.
- at least one cyclodextrin is an unsubstituted cyclodextrin.
- the one or more cyclodextrins are selected from the group consisting of unsubstituted cyclodextrins.
- at least one cyclodextrin is a substituted cyclodextrin.
- the one or more cyclodextrins are selected from the group consisting of substituted cyclodextrins.
- the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, substituted (a)-cyclodextrin, unsubstituted ⁇ )-cyclodextrin, substituted ⁇ )-cyclodextrin, unsubstituted (y)-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof.
- the one or more cyclodextrins are selected from the group consisting of unsubstituted ⁇ )-cyclodextrin, substituted ⁇ )-cyclodextrin, and mixtures thereof.
- the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, unsubstituted ⁇ )-cyclodextrin, unsubstituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from unsubstituted ⁇ )-cyclodextrin.
- the one or more cyclodextrins are selected from the group consisting of substituted (a)-cyclodextrin, substituted ⁇ )-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from substituted ⁇ -cyclodextrins. Chemical substitutions at the 2-, 3-, and 6-hydroxyl sites are envisaged, and in particular substitution at the 2-position.
- the one or more cyclodextrins are selected from the group consisting of 2- hydroxy-propyl-a-cyclodextrin, 2-hydroxy-propyl ⁇ -cyclodextrin, 2-hydroxy-propyl-y- cyclodextrin and mixtures thereof.
- the one or more cyclodextrins is at least 2- hydroxy-propyl-a-cyclodextrin.
- the one or more cyclodextrins is at least 2- hydroxy-propyl ⁇ -cyclodextrin.
- the one or more cyclodextrins is at least 2- hydroxy-propyl-y-cyclodextrin.
- 2-hydroxy-propyl derivatives of cyclodextrins such as 2-hydroxy-propyl ⁇ -cyclodextrin have increased solubility in water when compared to base cyclodextrins such as b-cyclodextrin.
- the aerosolisable formulation contains cyclodextrins in a total amount of no greater than 0.001 wt.% based on the aerosolisable formulation, such as cyclodextrins in a total amount of no greater than 1x1 O 4 wt.% based on the aerosolisable formulation, such as cyclodextrins in a total amount of no greater than 1x10 5 wt.% based on the aerosolisable formulation, such as cyclodextrins in a total amount of no greater than 1x10 6 wt.% based on the aerosolisable formulation.
- the present invention provides (1) an aerosolisable formulation comprising
- cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
- cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
- cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
- a power supply comprising a cell or battery for supplying power to the aerosoliser
- cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
- a process for forming an aerosol comprising aerosolising an aerosolisable formulation comprising
- the aerosol may be formed by a process performed at a temperature below 60°C.ln the process the aerosol may be formed by a process performed at a temperature below 50°C. In the process the aerosol may be formed by a process performed at a temperature below 40°C. In the process the aerosol may be formed by a process performed at a temperature below 30°C. In the process the aerosol may be formed by a process performed at a temperature below 25°C. In the process the aerosol may be formed by a process which does not involve heating.
- the aerosol may be formed by applying ultrasonic energy to the aerosolisable formulation.
- the aerosol of the aerosolised formulation has a D50 of from 2 to 6pm.
- References in the present specification to particle size distribution, D50, D10 or D90 refer to values measured in accordance with British and European Pharmacopoeia, 2.9.31 Particle Size Analysis By Laser Light Diffraction (see BRITISH PHARMACOPOEIA COMMISSION. (2014), British Pharmacopoeia. London, England: Stationery Office and COUNCIL OF EUROPE. (2013). European Pharmacopoeia. France: Council of Europe).
- the terms D50, Dv50 and Dx50 are interchangeable.
- the terms D10, Dv10 and Dx10 are interchangeable.
- the terms D90, Dv90 and Dx90 are interchangeable.
- the aerosol has a D50 of from 2.5 to 6pm. In one aspect the aerosol has a D50 of from 3 to 6pm. In one aspect the aerosol has a D50 of from 3.5 to 6pm. In one aspect the aerosol has a D50 of from 4 to 6pm. In one aspect the aerosol has a D50 of from 4.5 to 6pm. In one aspect the aerosol has a D50 of from 5 to 6pm. In one aspect the aerosol has a D50 of from 2.5 to 5.5pm. In one aspect the aerosol has a D50 of from 3 to 5.5pm. In one aspect the aerosol has a D50 of from 3.5 to 5.5pm. In one aspect the aerosol has a D50 of from 4 to 5.5pm. In one aspect the aerosol has a D50 of from 4.5 to 5.5pm. In one aspect the aerosol has a D50 of from 5 to 5.5pm.
- the aerosol has a D10 of at least 0.5pm. In one aspect the aerosol has a D10 of at least 1 pm. In one aspect the aerosol has a D10 of at least 2pm.
- the aerosol has a D90 of no greater than 15pm. In one aspect the aerosol has a D90 of no greater than 12pm. In one aspect the aerosol has a D90 of no greater than 10pm.
- D50 is measured after exclusion of particles having a particle size of less than 1 pm. In one aspect D10 is measured after exclusion of particles having a particle size of less than 1 pm. In one aspect D90 is measured after exclusion of particles having a particle size of less than 1 pm.
- the formulation may be contained or delivered by any means.
- the present invention provides a contained aerosolisable formulation comprising (a) one or more containers; and (b) an aerosolisable formulation as defined herein.
- the container may be any suitable container, for example to allow for the storage or delivery of the formulation.
- the container is configured for engagement with an electronic aerosol provision system.
- the container may be configured to become fluidly in communication with an electronic aerosol provision system so that formulation may be delivered to the electronic aerosol provision system.
- the present disclosure relates to container which may be used in an electronic aerosol provision system, such as an e-cigarette. Throughout the following description the term“e-cigarette” is used; however, this term may be used interchangeably with electronic aerosol provision system.
- the container of the present invention is typically provided for the delivery of aerosolisable formulation to or within an e-cigarette.
- the aerosolisable formulation may be held within an e-cigarette or may be sold as a separate container for subsequent use with or in an e-cigarette.
- e-cigarettes may contain a unit known as a detachable cartomiser which typically comprises a reservoir of aerosolisable formulation, an aerosoliser such as a wick material and a heating element for vaporising the aerosolisable formulation.
- the cartomiser is part of a single-piece device and is not detachable.
- the container is a cartomiser or is part of a cartomiser.
- the container is not a cartomiser or part of a cartomiser and is a container, such as a tank, which may be used to deliver nicotine formulation to or within an e-cigarette.
- the container is part of an e-cigarette. Therefore in a further aspect the present invention provides an electronic aerosol provision system comprising: an aerosolisable formulation as defined herein; an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system; and a power supply comprising a cell or battery for supplying power to the aerosoliser.
- the process of the present invention may comprises additional steps either before the steps listed, after the steps listed or between one or more of the steps listed.
- Figure 1 shows a graph illustrating variation of p s K a 2with nicotine concentration
- The“control” device was loaded with formulation containing 90.0% (w/w) water, 8.8% (w/w) propylene glycol containing flavour, and 1.2% (w/w) nicotine.
- a similar device was prepared wherein 5.0% w/w glycerol and 5.0% (w/w) propylene glycol was added to the formulation, with the water content was commensurately adjusted to 80.0% (w/w).
- a similar device was prepared wherein 10.0% w/w glycerol and 10.0% propylene glycol was added to the formulation, with the water content was commensurately adjusted to 70.0% (w/w).
- 10.0% w/w glycerol and 10.0% propylene glycol was added to the formulation, with the water content was commensurately adjusted to 70.0% (w/w).
- One each of these devices was presented to 8 panellists comprising e-cigarette users, and the panellists were asked to puff on the devices in a sequential monadic fashion for 5 puffs on each device. Each panellist was asked to choose a palatable flavour of their choosing to aid feedback regarding water, glycerol and propylene glycol composition.
- the devices were loaded with formulations containing
- Formulation 1 82% (w/w) water, 9.4% (w/w) 2-hydroxy-propyl ⁇ -cyclodextrin, 8% (w/w) glycerol, and 0.6% (w/w) nicotine.
- Formulation 2 - 85% (w/w) water, 9.4% (w/w) 2-hydroxy-propyl ⁇ -cyclodextrin, 5% (w/w) glycerol, and 0.6% (w/w) nicotine.
- Formulation 3 87% (w/w) water, 9.4% (w/w) 2-hydroxy-propyl ⁇ -cyclodextrin, 3% (w/w) glycerol, and 0.6% (w/w) nicotine.
- Formulation 4 82% (w/w) water, 2.0% (w/w) propylene glycol containing amaretto flavour, 9.8% (w/w) glycerol, 5% (w/w) ethanol, 0.6% (w/w) nicotine and 0.6% (w/w) citric acid.
- Formulation 5 - 85% (w/w) water, 2.0% (w/w) propylene glycol containing amaretto flavour, 6.8% (w/w) glycerol, 5% (w/w) ethanol, 0.6% (w/w) nicotine and 0.6% (w/w) citric acid.
- Formulation 6 87% (w/w) water, 2.0% (w/w) propylene glycol containing amaretto flavour, 4.8% (w/w) glycerol, 5% (w/w) ethanol, 0.6% (w/w) nicotine and 0.6% (w/w) citric acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Colloid Chemistry (AREA)
- Manufacture Of Tobacco Products (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112021008556-4A BR112021008556A2 (pt) | 2018-11-01 | 2019-10-31 | formulação aerossolizável, processo para formar um aerossol, formulação aerossolizável contida e sistema eletrônico de provisão de aerossol |
MX2021005123A MX2021005123A (es) | 2018-11-01 | 2019-10-31 | Formulacion aerosolizable. |
EP24152849.6A EP4353091A2 (fr) | 2018-11-01 | 2019-10-31 | Formulation aérosolisable |
CA3118051A CA3118051A1 (fr) | 2018-11-01 | 2019-10-31 | Formulation aerosolisable |
AU2019371079A AU2019371079B2 (en) | 2018-11-01 | 2019-10-31 | Aerosolisable formulation |
CN201980075317.2A CN113015444A (zh) | 2018-11-01 | 2019-10-31 | 可气雾化配制品 |
KR1020217012916A KR20210075107A (ko) | 2018-11-01 | 2019-10-31 | 에어로졸화 가능한 포뮬레이션 |
UAA202102224A UA128040C2 (uk) | 2018-11-01 | 2019-10-31 | Склад, здатний до утворення аерозолю |
JP2021523256A JP2022506094A (ja) | 2018-11-01 | 2019-10-31 | エアロゾル化可能な配合物 |
EP19798365.3A EP3873245B1 (fr) | 2018-11-01 | 2019-10-31 | Formulation aérosolisable |
US17/290,319 US20210386110A1 (en) | 2018-11-01 | 2019-10-31 | Aerosolisable formulation |
IL282523A IL282523A (en) | 2018-11-01 | 2021-04-21 | Aerosol formulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1817865.7A GB201817865D0 (en) | 2018-11-01 | 2018-11-01 | Aerosolisable formulation |
GB1817865.7 | 2018-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020089637A1 true WO2020089637A1 (fr) | 2020-05-07 |
Family
ID=64655353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2019/053092 WO2020089637A1 (fr) | 2018-11-01 | 2019-10-31 | Formulation aérosolisable |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210386110A1 (fr) |
EP (2) | EP4353091A2 (fr) |
JP (1) | JP2022506094A (fr) |
KR (1) | KR20210075107A (fr) |
CN (1) | CN113015444A (fr) |
AU (1) | AU2019371079B2 (fr) |
BR (1) | BR112021008556A2 (fr) |
CA (1) | CA3118051A1 (fr) |
GB (1) | GB201817865D0 (fr) |
IL (1) | IL282523A (fr) |
MX (1) | MX2021005123A (fr) |
UA (1) | UA128040C2 (fr) |
WO (1) | WO2020089637A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022043666A1 (fr) | 2020-08-27 | 2022-03-03 | Nicoventures Trading Limited | Consommable |
US11771132B2 (en) | 2020-08-27 | 2023-10-03 | Rai Strategic Holdings, Inc. | Atomization nozzle for aerosol delivery device |
US11771136B2 (en) | 2020-09-28 | 2023-10-03 | Rai Strategic Holdings, Inc. | Aerosol delivery device |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201817859D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
IT202100022172A1 (it) * | 2021-08-23 | 2023-02-23 | Natural Acad S R L | Composizione liquida medicale per somministrazione aerea |
KR20240028723A (ko) * | 2022-08-25 | 2024-03-05 | 주식회사 케이티앤지 | 산을 포함하는 흡연물품 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040034068A1 (en) * | 2002-06-03 | 2004-02-19 | Woodcock Washburn Llp | New formulation and use thereof |
DE102015117811A1 (de) * | 2015-10-20 | 2017-04-20 | Chv Pharma Gmbh & Co. Kg | Inhalator sowie wirkstoffhaltige Zubereitung für einen Inhalator |
WO2019086858A1 (fr) * | 2017-11-01 | 2019-05-09 | British American Tobacco (Investments) Limited | Formulation aérosolisable |
EP3574902A1 (fr) * | 2018-06-01 | 2019-12-04 | Yatzz Limited | Formulation de nicotine et mode d'administration |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0462094U (fr) * | 1990-10-09 | 1992-05-27 | ||
AU717600B2 (en) * | 1993-07-26 | 2000-03-30 | Mcneil Ab | Improved nicotine lozenge and therapeutic method for smoking cessation |
US20080138399A1 (en) * | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
US20030159702A1 (en) * | 2002-01-21 | 2003-08-28 | Lindell Katarina E.A. | Formulation and use manufacture thereof |
PL378270A1 (pl) * | 2002-12-31 | 2006-03-20 | Nektar Therapeutics | Preparat farmaceutyczny zawierający nierozpuszczalny środek czynny |
SE0300520D0 (sv) * | 2003-02-28 | 2003-02-28 | Pharmacia Ab | A container comprising nicotine and the use and manufacture thereof |
US20070267033A1 (en) * | 2006-02-09 | 2007-11-22 | Philip Morris Usa Inc. | Gamma cyclodextrin flavoring-release additives |
CN101583354A (zh) * | 2006-12-01 | 2009-11-18 | 阿拉迪姆公司 | 用于终止烟草使用的系统 |
GB0700889D0 (en) * | 2007-01-17 | 2007-02-21 | British American Tobacco Co | Tobacco, tobacco derivative and/or tobacco substitute products, preparation and uses thereof |
US20080286340A1 (en) * | 2007-05-16 | 2008-11-20 | Sven-Borje Andersson | Buffered nicotine containing products |
GB0918129D0 (en) * | 2009-10-16 | 2009-12-02 | British American Tobacco Co | Control of puff profile |
US9333229B2 (en) * | 2013-10-16 | 2016-05-10 | William Bjorncrantz | Winterized crude cannabis extracts and methods of preparation and use |
TWI664918B (zh) * | 2014-05-21 | 2019-07-11 | 瑞士商菲利浦莫里斯製品股份有限公司 | 可感應加熱的菸草產品 |
GB2528673B (en) * | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
GB201413835D0 (en) * | 2014-08-05 | 2014-09-17 | Nicoventures Holdings Ltd | Electronic vapour provision system |
US20190116863A1 (en) * | 2017-10-24 | 2019-04-25 | Rai Strategic Holdings, Inc. | Method for formulating aerosol precursor for aerosol delivery device |
GB201817859D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
-
2018
- 2018-11-01 GB GBGB1817865.7A patent/GB201817865D0/en not_active Ceased
-
2019
- 2019-10-31 JP JP2021523256A patent/JP2022506094A/ja active Pending
- 2019-10-31 CN CN201980075317.2A patent/CN113015444A/zh active Pending
- 2019-10-31 CA CA3118051A patent/CA3118051A1/fr active Pending
- 2019-10-31 EP EP24152849.6A patent/EP4353091A2/fr active Pending
- 2019-10-31 US US17/290,319 patent/US20210386110A1/en active Pending
- 2019-10-31 EP EP19798365.3A patent/EP3873245B1/fr active Active
- 2019-10-31 UA UAA202102224A patent/UA128040C2/uk unknown
- 2019-10-31 AU AU2019371079A patent/AU2019371079B2/en active Active
- 2019-10-31 KR KR1020217012916A patent/KR20210075107A/ko active IP Right Grant
- 2019-10-31 MX MX2021005123A patent/MX2021005123A/es unknown
- 2019-10-31 BR BR112021008556-4A patent/BR112021008556A2/pt unknown
- 2019-10-31 WO PCT/GB2019/053092 patent/WO2020089637A1/fr unknown
-
2021
- 2021-04-21 IL IL282523A patent/IL282523A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040034068A1 (en) * | 2002-06-03 | 2004-02-19 | Woodcock Washburn Llp | New formulation and use thereof |
DE102015117811A1 (de) * | 2015-10-20 | 2017-04-20 | Chv Pharma Gmbh & Co. Kg | Inhalator sowie wirkstoffhaltige Zubereitung für einen Inhalator |
WO2019086858A1 (fr) * | 2017-11-01 | 2019-05-09 | British American Tobacco (Investments) Limited | Formulation aérosolisable |
EP3574902A1 (fr) * | 2018-06-01 | 2019-12-04 | Yatzz Limited | Formulation de nicotine et mode d'administration |
Non-Patent Citations (4)
Title |
---|
"BRITISH PHARMACOPOEIA COMMISSION", 2014 |
"British Pharmacopoeia", 2013, STATIONERY OFFICE AND COUNCIL OF EUROPE |
"European Pharmacopoeia", COUNCIL OF EUROPE |
PETER M. CLAYTONCARL A. VASTAM T. T. BUIALEX F. DRAKEKEVIN MCADAM: "Spectroscopic investigations into the acid-base properties of nicotine at different temperatures", ANAL. METHODS, vol. 5, 2013, pages 81 - 88 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022043666A1 (fr) | 2020-08-27 | 2022-03-03 | Nicoventures Trading Limited | Consommable |
US11771132B2 (en) | 2020-08-27 | 2023-10-03 | Rai Strategic Holdings, Inc. | Atomization nozzle for aerosol delivery device |
US11771136B2 (en) | 2020-09-28 | 2023-10-03 | Rai Strategic Holdings, Inc. | Aerosol delivery device |
Also Published As
Publication number | Publication date |
---|---|
AU2019371079B2 (en) | 2022-07-14 |
GB201817865D0 (en) | 2018-12-19 |
UA128040C2 (uk) | 2024-03-20 |
CN113015444A (zh) | 2021-06-22 |
IL282523A (en) | 2021-06-30 |
MX2021005123A (es) | 2021-06-15 |
EP3873245B1 (fr) | 2024-02-28 |
AU2019371079A1 (en) | 2021-05-27 |
US20210386110A1 (en) | 2021-12-16 |
EP3873245A1 (fr) | 2021-09-08 |
CA3118051A1 (fr) | 2020-05-07 |
JP2022506094A (ja) | 2022-01-17 |
EP4353091A2 (fr) | 2024-04-17 |
KR20210075107A (ko) | 2021-06-22 |
BR112021008556A2 (pt) | 2021-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019371079B2 (en) | Aerosolisable formulation | |
AU2019373768B2 (en) | Aerosolisable formulation | |
AU2019371078B2 (en) | Aerosolisable formulation | |
AU2019370809B2 (en) | Aerosolisable formulation | |
AU2019370808B2 (en) | Aerosolisable formulation | |
AU2019372222B2 (en) | Aerosolisable formulation | |
RU2800011C2 (ru) | Способная образовывать аэрозоль композиция |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19798365 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021523256 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3118051 Country of ref document: CA Ref document number: 20217012916 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021008556 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019371079 Country of ref document: AU Date of ref document: 20191031 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019798365 Country of ref document: EP Effective date: 20210601 |
|
ENP | Entry into the national phase |
Ref document number: 112021008556 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210503 |